Contributions
Abstract: P336
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Diagnosis and differential diagnosis
Introduction: As a broad spectrum of disease entities, variable signs of onset potentially pose a challenge to early identification and treatment of MOG antibody-associated demyelination.
Objective: To analyze the clinical and prognostic features of MOG antibody-associated demyelination with different onset phenotypes.
Aims: To investigate the implication of first demyelinating event to whole disease course and future prognosis.
Methods: A total of 52 MOG-IgG seropositive patients identified by cell-based assay were divided into four groups: (i) ON at onset (MOG-ON+, n=23); (ii) TM at onset (MOG-TM+, n=12); (iii) pure brain symptoms at onset (MOG-ON－TM－, n=14); (iv) both ON and TM at onset (n=3, not included into analyze). Data were collected through medical records and regular follow-up.
Results: MOG-ON－TM－ had the youngest age of onset. Patients with MOG-TM+ tended to relapse more frequently, with a longer interval to first relapse compared to those with MOG-ON+ and MOG-ON－TM－. Throughout the course, 21%-33% of patients had clinical evidence of other attack localization except their initial ones. High MOG-IgG titers were associated with increased CSF leukocytes. There was a trend towards greater likelihood of haboring transient, low MOG-IgG titers in MOG-TM+ vs the other groups. The majority of MOG-TM+ and MOG-ON+ had radiologic brain involvement, but the frequency of abnormal MRI and large brain lesion were predominately lower than the MOG-ON－TM－. After a median disease duration of 20 months, most cases exhibited a favourable outcome, but not always, with 13% developing severe visual deficits, 2% becoming wheelchair dependent and 6% developing cognitive impairment. The onset phenotype appeared to be an important predictor of disability type. Having ON at onset (OR 2.27, p=0.047) was more likely to achieve a complete recovery, while having high MOG-IgG titers (OR 0.14, p=0.025) was less likely to recover fully.
Conclusions: Onset phenotype may influence long-term presentation, MOG-IgG status as well as the outcome. Further large and prospective studies will be required to better clarify the clinical relevance of MOG-IgG and the first demyelinating attack.
Disclosure: Name: nothing to disclose
Abstract: P336
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Diagnosis and differential diagnosis
Introduction: As a broad spectrum of disease entities, variable signs of onset potentially pose a challenge to early identification and treatment of MOG antibody-associated demyelination.
Objective: To analyze the clinical and prognostic features of MOG antibody-associated demyelination with different onset phenotypes.
Aims: To investigate the implication of first demyelinating event to whole disease course and future prognosis.
Methods: A total of 52 MOG-IgG seropositive patients identified by cell-based assay were divided into four groups: (i) ON at onset (MOG-ON+, n=23); (ii) TM at onset (MOG-TM+, n=12); (iii) pure brain symptoms at onset (MOG-ON－TM－, n=14); (iv) both ON and TM at onset (n=3, not included into analyze). Data were collected through medical records and regular follow-up.
Results: MOG-ON－TM－ had the youngest age of onset. Patients with MOG-TM+ tended to relapse more frequently, with a longer interval to first relapse compared to those with MOG-ON+ and MOG-ON－TM－. Throughout the course, 21%-33% of patients had clinical evidence of other attack localization except their initial ones. High MOG-IgG titers were associated with increased CSF leukocytes. There was a trend towards greater likelihood of haboring transient, low MOG-IgG titers in MOG-TM+ vs the other groups. The majority of MOG-TM+ and MOG-ON+ had radiologic brain involvement, but the frequency of abnormal MRI and large brain lesion were predominately lower than the MOG-ON－TM－. After a median disease duration of 20 months, most cases exhibited a favourable outcome, but not always, with 13% developing severe visual deficits, 2% becoming wheelchair dependent and 6% developing cognitive impairment. The onset phenotype appeared to be an important predictor of disability type. Having ON at onset (OR 2.27, p=0.047) was more likely to achieve a complete recovery, while having high MOG-IgG titers (OR 0.14, p=0.025) was less likely to recover fully.
Conclusions: Onset phenotype may influence long-term presentation, MOG-IgG status as well as the outcome. Further large and prospective studies will be required to better clarify the clinical relevance of MOG-IgG and the first demyelinating attack.
Disclosure: Name: nothing to disclose